NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

中樞神經系統治療市場——COVID-19 的增長、趨勢、影響和預測(2021-2026)

Central Nervous System Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 1008461
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
中樞神經系統治療市場——COVID-19 的增長、趨勢、影響和預測(2021-2026) Central Nervous System Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
出版日期: 2021年05月13日內容資訊: 英文 120 Pages
簡介

預計在 2021-2026 年的預測期內,CNS 治療藥物市場的複合年增長率約為 5.9%。

越來越多的中樞神經系統疾病患者可能是促進中樞神經系統治療市場增長的關鍵因素。根據世界衛生組織的數據,中風和阿爾茨海默病是 2019 年世界第二和第七大死亡原因。此外,預計仿製藥的增加將促進神經藥物向低收入和中等收入國家的滲透,使它們能夠負擔得起。納米顆粒等給藥系統的創新也為新藥創造了機會。預計這些因素將有助於 CNS 治療市場的增長。

研發是一個複雜的過程,也是製藥行業的一項重要決策。這包括在新藥上市前對新藥的安全性和有效性以及對監管指南的遵守情況進行深入研究。此外,研發支出並不總是會產生更高的回報,並且會阻礙製藥公司投資 CNS 治療。此外,據報導某些 CNS 藥物(如抗癲癇藥)的副作用會阻礙整個市場的增長。

本報告調查了全球 CNS 市場,分析了市場概況、市場增長和障礙、市場機會、區域市場規模趨勢和預測、競爭條件、主要參與者。我們提供了公司簡介等。

目錄

第 1 章介紹

第二章調查方法

第 3 章執行摘要

第 4 章市場動態

  • 市場概覽
  • 市場驅動力
    • 中樞神經系統疾病負擔加重
    • 仿製藥增加
    • 新型給藥系統的開發
  • 市場限制
    • 與 CNS 治療相關的不良事件
    • 研發成本高
  • 波特五力分析

第 5 章市場細分

  • 因病
    • 神經血管疾病
    • 創傷
    • 心理健康
    • 退行性疾病
    • 傳染病
    • 癌症
    • 其他
  • 按藥物類別
    • 止痛藥
    • 神經系統藥物
    • 麻醉劑
    • 抗帕金森藥
    • 抗癲癇
    • 其他藥物類別
  • 地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 南美洲

第6章競爭形勢

  • 公司簡介
    • Biogen
    • Otsuka Pharmaceutical Co. Ltd
    • Eli Lilly and Company
    • Merck KGaA
    • AstraZeneca
    • Takeda Pharmaceutical Coompany Limited
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
    • Johnson &Johnson Private Limited
    • Pfizer Inc.
    • GlaxoSmithKline PLC

第7章 市場機會動向

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 71993

The central nervous system (CNS) therapeutics market is projected to register a CAGR of nearly 5.9% over the forecast period (2021 - 2026).

With the increasing COVID-19 cases, worldwide, healthcare services diverted all resources toward patients suffering from COVID-19 disease. Although COVID-19 severely affects the respiratory system, it has been reported to show effects on central and peripheral systems. These included encephalopathy, inflammation, ischaemic stroke, and peripheral neurological disorders. A research study published in JAMA Neurology involving 214 patients in China showed that patients with severe illness from COVID-19 had neurologic manifestations of acute cerebrovascular disease, impaired consciousness, and skeletal muscle injury. Additionally, clinical trials on the repurposing of anti-depressants for COVID-19 may have minimal impact on the CNS therapeutics market.

An increase in the number of patients suffering from CNS disease is likely to be the key factor contributing to the growth of the CNS therapeutics market. According to the WHO, in 2019, stroke and Alzheimer's are the second and seventh top-most causes for deaths, globally. A study published in The Lancet finds that neurological diseases are the third common cause of disability and premature deaths and are estimated to increase with age in Europe. Additionally, a rise in generics is expected to drive the penetration of neurologic drugs to lower and middle-income countries, making them affordable. Along with this, increasing awareness programs may result in drugs being easily accessible. Innovation in drug delivery systems, such as nanoparticles, creates opportunities for new drugs. A recent Rutgers research in 2020 was conducted for the treatment of neurological disorders, by creating a micro-environment and suppressing inflammation using nanomaterials, polymers, and neural proteins. Therefore, all the above factors are expected to contribute to the growth of the CNS therapeutics market.

R&D is a complex process and an important decision within the pharmaceutical industry. It involves a detailed study of the safety and efficacy of novel drugs, along with meeting regulatory guidelines before releasing them into the market. According to the analysis by Tufts Center for the Study of Drug Development in 2018, CNS drug development is 20% more time-consuming and takes 38% longer time to get approved than other non-CNS drugs. Moreover, expenditure in R&D may not always yield higher returns, making it a risky investment. As a result, drugs are priced higher to recover the spending. Hence, risky R&D spending for developing CNS drugs may discourage pharmaceutical companies from investing in CNS therapeutics. Furthermore, adverse reactions reported for certain CNS drugs, such as anti-epileptic drugs, may inhibit the overall market growth.

Key Market Trends

Degenerative Disease is Expected to Dominate the CNS Therapeutics Market over the Forecast Period

The degenerative disease segment occupies a major share of the market over the forecast period (2021 - 2026). This disease occurs when nerve cells in the brain and peripheral nervous systems lose their function and die. The major share of it is attributed to the increasing prevalence of Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

According to the WHO, globally, 50 million people suffer from dementia, with nearly 60% living in low and middle-income countries. It estimates the number to reach 82 million by 2030. Atlas of MS shows that 2.8 million people live with multiple sclerosis worldwide and 10 million with Parkinson's disease as per the Parkinson's Foundation. The treatment options for these diseases are very few. Currently, five approved drugs are widely used for Alzheimer's, and 146 clinical studies are recruiting, which are in Phases 1, 2, and 3. Recently, FDA approved Ongentys capsules for Parkinson's disease when a patient's medications are not working well and Zeposia capsules for relapsing forms of multiple sclerosis. According to Alzheimer's Europe, it is estimated that about 7.8 million individuals in the European Union are with dementia. Furthermore, the Harvard NeuroDiscovery Center estimates that nearly 12 million Americans may suffer from neurodegenerative diseases 30 years from now if there are no measures taken. Therefore, the rise in prevalence of these diseases, drug development pipeline, and the potential of this segment opens opportunities for clinical studies, product launches, and strategic collaborations.

North America is Expected to Dominate the Central Nervous System Therapeutics Market

North America is expected to dominate the CNS therapeutics market over the forecast period (2021 - 2026).

According to GBD 2019, neurological disorders ranked third for the cause of deaths in Canada and fourth in the United States. The Alzheimer's Disease Fact and Figures Report estimated that 5.8 million Americans are living with dementia, among which 5.6 million are aged 65 years and above in 2019. The same source also reports that the total costs for Alzheimer's were USD 290 billion, which includes Medicare (51%), Medicaid (17%), Out of Pocket (22%), and other costs (11%).

Government funding and support for research activities are increasing due to the rising burden of the disease. The US congress invested about USD 10 million in multiple sclerosis research and may increase the funding by USD 20 million. CDC established a National Neurological Conditions Surveillance System (NNCSS) for tracking the disease. In 2019, Canada released its first national strategy for tackling dementia. The Canadian Institutes of Health Research spent around USD 200 million for research activities on dementia, and it is providing an additional USD 31.6 million over 5 years, which is likely to bring together individuals for advanced research opportunities. A large number of clinical studies are undergoing in North America, especially in the United States. Among the total neurological disease clinical studies being conducted, worldwide, more than half are in the United States. In March 2021, US President Biden signed the American Rescue Plan Act 2021. According to the act, a portion of spending is allotted to mental health services, further increasing the government activities toward neurological diseases. The rising burden of the disease and healthcare infrastructure and supportive government initiatives make North America a very attractive opportunity for industries.

Competitive Landscape

The central nervous system therapeutics market remains moderately competitive, with key players in the market. However, the need for innovation in the treatment and drug delivery system and clinical trials and strategic collaboration is likely to help companies maintain their market position. Some of the major players include Biogen Inc, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Company, Merck & Co., AstraZeneca, Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Private Limited, Pfizer Inc., and GlaxoSmithKline PLC.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Burden of CNS Disorders
    • 4.2.2 Increase in Generic Drugs
    • 4.2.3 Development of Novel Drug Delivery Systems
  • 4.3 Market Restraints
    • 4.3.1 Adverse Events Associated with CNS Therapeutics
    • 4.3.2 High R&D Costs
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Disease
    • 5.1.1 Neurovascular Diseases
    • 5.1.2 Trauma
    • 5.1.3 Mental Health
      • 5.1.3.1 Anxiety Disorders
      • 5.1.3.2 Epilepsy
      • 5.1.3.3 Psychotic Disorders
      • 5.1.3.4 Others
    • 5.1.4 Degenerative Diseases
      • 5.1.4.1 Alzheimer's Disease
      • 5.1.4.2 Parkinson's Disease
      • 5.1.4.3 Multiple Sclerosis
      • 5.1.4.4 Amyotrophic Lateral Sclerosis
      • 5.1.4.5 Others
    • 5.1.5 Infectious Diseases
    • 5.1.6 Cancer
    • 5.1.7 Others
  • 5.2 By Drug Class
    • 5.2.1 Analgesics
    • 5.2.2 Nervous System Drugs
    • 5.2.3 Anesthetics
    • 5.2.4 Anti-Parkinson Drugs
    • 5.2.5 Anti-Epileptics
    • 5.2.6 Other Drug Classes
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Biogen
    • 6.1.2 Otsuka Pharmaceutical Co. Ltd
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 Merck KGaA
    • 6.1.5 AstraZeneca
    • 6.1.6 Takeda Pharmaceutical Coompany Limited
    • 6.1.7 Novartis AG
    • 6.1.8 Teva Pharmaceutical Industries Ltd
    • 6.1.9 Johnson & Johnson Private Limited
    • 6.1.10 Pfizer Inc.
    • 6.1.11 GlaxoSmithKline PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS